Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 26;14(2):286.
doi: 10.3390/pharmaceutics14020286.

Nanostructured Drug Delivery Systems for Targeting 5-α-Reductase Inhibitors to the Hair Follicle

Affiliations
Review

Nanostructured Drug Delivery Systems for Targeting 5-α-Reductase Inhibitors to the Hair Follicle

Silvia Tampucci et al. Pharmaceutics. .

Abstract

Androgenetic alopecia is a multifactorial condition characterized by noticeable hair loss, affecting both men and women and representing a debilitating and chronic disorder that considerably affects the quality of life. Available topical treatments based on minoxidil or finasteride require repeated applications and are associated with a certain number of adverse effects. The challenges associated with current treatments pave the way for the research of new therapeutic strategies, more precise and selective, and capable of providing long-term results. In this context, the present review examines the new proposed formulation strategies to deliver 5-α-reductase inhibitors in order to obtain a targeted drug delivery, for improving drug retention at the site of action in the hair follicle, contemporaneously reducing drug systemic absorption, which is the cause of important adverse effects. In particular, the research will be focused on the several aspects that influence the performance of nanostructured drug delivery systems in creating a depot in the hair follicles, such as particle size, surface charge, excipients, and combined application with external stimuli (infrared radiation, mechanical massage, ultrasounds application).

Keywords: androgenetic alopecia; drug delivery; dutasteride; finasteride; hair follicle; nanostructures; skin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The normal hair cycle.
Figure 2
Figure 2
Potential routes for a molecule to cross the skin.
Figure 3
Figure 3
Penetration depths (µm) of different sizes of PLGA particles related to the target sites in terminal hair follicles (THF) and vellus hair follicles (VHF) (Reproduced from Blume-Peytavi et al. [18] which is licensed under a Creative Commons Attribution-(CC BY 4.0) International License http://creativecommons.org/licenses/by/4.0/).

References

    1. Stough D., Stenn K., Haber R., Parsley W.M., Vogel J.E., Whiting D.A., Washenik K. Psychological effect, pathophysiology, and management of androgenetic alopecia in men. Mayo Clin. Proc. 2005;80:1316–1322. doi: 10.4065/80.10.1316. - DOI - PubMed
    1. Monti D., Tampucci S., Burgalassi S., Chetoni P., Lenzi C., Pirone A., Mailland F. Topical formulations containing finasteride. Part I: In vitro permeation/penetration study and in vivo pharmacokinetics in hairless rat. J. Pharm. Sci. 2014;103:2307–2314. doi: 10.1002/jps.24028. - DOI - PubMed
    1. Motofei I.G., Rowland D.L., Baconi D.L., Tampa M., Sârbu M.I., Păunică S., Constantin V.D., Bălălău C., Păunică I., Georgescu S.R. Androgenetic alopecia; drug safety and therapeutic strategies. Expert Opin. Drug Saf. 2018;17:407–412. doi: 10.1080/14740338.2018.1430765. - DOI - PubMed
    1. Ellis J.A., Sinclair R., Harrap S.B. Androgenetic alopecia: Pathogenesis and potential for therapy. Expert Rev. Mol. Med. 2002;4:1–11. doi: 10.1017/S1462399402005112. - DOI - PubMed
    1. Redler S., Messenger A.G., Betz R.C. Genetics and other factors in the aetiology of female pattern hair loss. Exp. Dermatol. 2017;26:510–517. doi: 10.1111/exd.13373. - DOI - PubMed

LinkOut - more resources